DOI: https://doi.org/10.22263/2312-4156.2016.1.85
Moiseyeva A.M.*, Moiseyev D.V.*, Veremchuk O.A.*, Lukashov R.I.*, Syukhin D.A.**
Medicines of monoclonal antibodies in the Republic of Belarus
*Educational Establishment «Vitebsk State Order of Peoples’ Friendship Medical University», Vitebsk, Republic of Belarus
**Limited Liability Company «Intellix-M», Minsk, Republic of Belarus
Vestnik VGMU. 2016;15(1):85-92.
Abstract.
The assortment and dynamics of the sales of medicines on the basis of monoclonal antibodies (MAB) present on the pharmaceutical market of the Republic of Belarus in 2008 – 2015 years were studied, the most demanded in the clinic medicines were determined. Sales over the indicated period equaled about 125,4 millions USD; 90,1% of this amount made up the sales of anticancer MAB medicines, 6,8% – MAB medicines for prevention of graft rejection, 3,0% – MAB medicines for the treatment of autoimmune diseases. In the Republic of Belarus 26 medicines on the basis of MAB are registered. 18 of them were presented at the pharmaceutical market of the republic in 2008 – 2015 years. All MAB medicines, introduced to the pharmaceutical market of Belarus, are imported. The highest volumes of sales belong to anticancer medicines «Herceptin» (45,7% in money terms and 34,3% in the number of packages), «Mabthera» (27,3% and 30,6%, respectively), «Avastin» (15,3% and 19,3%, respectively). The average price of medicinal preparations was 1342,45 USD per pack. By the end of 2014 year sales of MAB preparations had increased 2,8 times in money terms, 3,2 times in the number of packages compared with 2008 year. Thus high-tech medicines on the basis of MAB are a promising segment of the pharmaceutical market. Local production of MAB pharmaceutical substances will allow to significantly reduce the cost of medicines and to use them for the treatment of a wide range of patients.
Key words: monoclonal antibodies, immunotherapy, medicine.
References
1. Avdeeva ZhI, Alpatova NA, Volkova RA, Lapteva LK. Lekarstvennye preparaty na osnove genno-inzhenernykh monoklonal’nykh antitel [Medicinal preparations on the basis of genetically engineered monoclonal antibodies]. Biopreparaty: profilaktika, diagnostika, lechenie. 2011;(2):14-9.
2. Yarilin AA. Immunologiia [Immunology]: uchebnik. Moscow, RF: GEOTAR-Media; 2010. 752 р.
3. Breedveld F. Therapeutic monoclonal antibodies. Lancet. 2000 Feb;355(9205):735-40.
4. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000 Jun;59(6):1341-59.
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of Trastuzumab as a single agent in firstline treatment of HER-2 overexpressing metastatic breast cancer (HER2+/MBC). J Clin Oncol. 2002 Feb;20(3):719-26.
6. Belozorov AP. Lekarstvennye preparaty gumanizirovannykh antitel [Medicinal preparations of the humanized antibodies]. Provizor. 2007;(2):30-4.
7. Yagudina RI, Tikhomirova AV. Lekarstvennye sredstva na osnove monoklonal’nykh antitel: proshloe nastoiashchee i budushchee [Medicines on the basis of monoclonal antibodies: past present and future]. Novaia apteka. Effektivnoe upravlenie. 2013;(12):51-5.
8. Tsybina A. Ataka monoklonov [Attack of monoclones]. Kommersant.ru. Meditsina. 2013 Okt 3;(180):28.
9. Reestr lekarstvennykh sredstv Respubliki Belarus’ [Register of medicines of Republic of Belarus] [Elektronnyi resurs]. Tsentr ekspertiz i ispytanii v zdravookhranenii: [sait]. Minsk, RB; 2014. Rezhim dostupa: http://www.rceth.by/Refbank/. Data dostupa: 19.10.2014.
10. Nikitin EA, Glazkova OI. «Volshebnye puli»: monoklonal’nye antitela v onkologii [«Magic bullets»: monoclonal antibodies in an oncology]. Lechashchii vrach. 2007;(6):73-5.
11. Krasilnikov IV. Perspektivy razvitiia rynka rekombinantnykh preparatov [Prospects of development of the market of recombinant drugs]. Farmatsevt Vestn. 2005 Май;(16):26.
